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Effect of a Hexylamine Derivative on Cancer Cell 
Viability
Rachel DeLancey, Bamlak Deju, Jeff Hansen, Ph.D., and Nipun Chopra Ph.D.
Department of Biology, DePauw University, Greencastle, IN
2-[(p-Chlorophenyl)hydroxymethyl]-1-[(methylamino)hexyl]cyclohexanol is a drug produced by 
hexyl amine and an epoxide through an aldol epoxidation reaction.  Motifs of β-amino alcohols 
and nonpolar R groups in organic compounds have been found to have cytotoxic properties.  Past 
studies in Dr. Hansen’s lab has shown that this hexylamine derivative has similar LC50 values to 
other antitumor agents. They also found that the drug was cytotoxic to HL-60 cancer cells.  No 
other cell lines have been tested with this drug.  Our study investigates the effect of our compound 
on varying cell lines to further determine its anticancer properties.  Mouse NIH/3T3, Human 
HEK293, and Human SK-MEL-28 cell lines were cultured and plated into 96-well plates.  
Varying concentrations of the hexylamine derivative were administered and incubated for 48 
hours.  MTT assays detected the levels of cell viability.  Results showed a significant decrease in 
HEK293 cells at a 30 µM concentration of our drug.  The mouse and cancer cell lines did not 
produce significant results after statistical ANOVA tests.  Future directions include further 
validation of the current results as well as research on the mechanisms by which this drug causes 
decreased cell viability.  This research includes LDH and wound healing assays in addition to 
determining which proteins are down- and up-regulated in the process.  Our study has found that 
the compound reduces human embryonic cell viability but does not significantly affect mouse 
cells or human melanoma cells. Further research is required to determine the methods of the drug 
and its potential in tumor treatment.
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The data shows that cell viability is significantly reduced at a 30 µM concentration of 
2-[(p-Chlorophenyl)hydroxymethyl]-1-[(methylamino)hexyl]cyclohexanol.  The 
SK-MEL-28 cells had significant results with the positive control and media treatments, but 
no significance from the drug treatments. The NIH/3T3 cells had no significant results and 
the data points were much different from the other two cell lines.  Causes for these 
differences could be that the drug affects mice cells differently from human cells, or that the 
methods were not run properly.
At this point, this compound does not show great promise as an anti-tumor agent.  The data 
suggests that the drug decreases cell viability in ‘healthy’ human cells more effectively than 
in human cancer cells.  As a result, it would not be a great option for targeting tumors.  
However, only melanoma cells were tested.  The drug may show stronger effects against 
other cancer types.
Conclusion
Future studies for this research should look at validating our data results and furthering 
the tests performed in our lab.  Repetition of the treatments and MTT treatments that we 
executed would confirm our results and their accuracy.  Several additional tests could be 
performed to further study the anti-tumor potential of this hexylamine derivative.  For 
example, an LDH assay would determine if the reduced cell viability was due to 
cytotoxic properties of the drug or some other mechanism.  We also considered 
performing a wound-healing assay to study the effects of the  drug had on cell migration.  
Future studies could also look into different cancer cell lines to determine if the drug is 
more effective in decreasing cell viability in other cell lines. Many studies could confirm 
or refute the results we found in this study.
Future Directions
Background
Cell Lines:  NIH/3T3 (mouse embryonic fibroblasts), SK-MEL-28 (human melanoma cells), 
HEK-293 (human embryonic kidney cells) 
Cell Culture:  DMEM with 10% Fetal Bovine Serum (FBS)  (NIH/3T3 and HEK-293), EMEM 
with 10% FBS (SK-MEL-28)
Drug Treatment: 2-[(p-Chlorophenyl)hydroxymethyl]-1-[(methylamino)hexyl]cyclohexanol 
dissolved in DMSO
MTT Assay:  MTT Reagent (3-(4, 5-dimethylthiazolyl-2)-2,
5-diphenyltetrazolium bromide), Detergent Reagent, spectrophotometer
Materials
Cell Culture and Drug Treatment:  Cells were cultured in media and FBS.  Once 
confluent, cells were split into a 96- well plate at 100k cells per well.  The hexylamine 
derivative was dissolved into DMSO.  Cells were assigned to treatment groups of untreated, 
various  hexylamine derivative concentrations, vehicle, or positive control.  0.01% DMSO 
was used as the vehicle treatment  to mimic the DMSO that was included in the drug 
treatment.  10% DMSO was used as the positive control because it is known to kill cells at 




Figure 1.  The response of NIH/3T3 cell viability to various concentrations of 
2-[(p-Chlorophenyl)hydroxymethyl]-1-[(methylamino)hexyl]cyclohexanol.  No significant results.
SK-MEL-28
Figure 2.  The response of SK-MEL-28  cell viability to various concentrations of 
2-[(p-Chlorophenyl)hydroxymethyl]-1-[(methylamino)hexyl]cyclohexanol.  Significant results 
between Untreated and Positive Control and Untreated and Media.
HEK-293
Figure 3.  The response of SK-MEL-28  cell viability to various concentrations of 
2-[(p-Chlorophenyl)hydroxymethyl]-1-[(methylamino)hexyl]cyclohexanol.  Significant results 
between Untreated and 30 µam, Untreated and Media, and Untreated and Positive Control.
Figure 2. The mechanism by which MTT Assays measure cell viability.  Greater amounts of 
formazin indicates greater cell viability.
MTT Assay:  10 µl of MTT Reagent was added to each well of treated cells.  The plate was 
placed in the dark at room temperature for 4 hours.  100 µl of detergent was added to break 
open the cell membrane.  The plate was stored in the dark at room temperature for another 4 
hours.  The plate was then removed and read by a spectrophotometer.  This measurement 
provided a quantification of cell viability.  We used Prism to run ANOVA statistical tests to 
determine significance. 
To create our compound, the epoxide ring was broken.  The ring was opened by primary and 
secondary amine nucleophiles that attacked the ring bonds through an Sn2 substitution reaction. 
This reaction is  catalyzed by the acetonitrile through a reflux reaction.  The reaction creates a 
β-amino alcohol component along with the hexylamine chain. This component plays a role in 
some anticancer agents in compounds such as hapalosin. When tested in Dr. Hansen’s lab at 
DePauw University, this compound had a lethal concentration of LC50 = 4.6 uM from a Brine 
Shrimp Assay.
Figure 1.  The chemical reaction that results in the epoxide compound (top).  The 
epoxide compound then reacts with hexylamine to create our compound (bottom).
